Wall Street analysts expect Oragenics, Inc. (NASDAQ:OGEN) to post earnings per share (EPS) of ($0.07) for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Oragenics’ earnings. Oragenics reported earnings of ($0.08) per share in the same quarter last year, which would indicate a positive year over year growth rate of 12.5%. The firm is expected to report its next earnings report on Thursday, November 12th.

On average, analysts expect that Oragenics will report full-year earnings of ($0.47) per share for the current year. For the next financial year, analysts anticipate that the business will report earnings of ($0.25) per share. Zacks’ earnings per share calculations are an average based on a survey of analysts that cover Oragenics.

Oragenics (NASDAQ:OGEN) last released its earnings results on Friday, August 14th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.15).

Oragenics stock opened at $0.75 on Friday. Oragenics has a 1 year low of $0.36 and a 1 year high of $2.09. The firm has a 50 day moving average price of $0.87 and a 200 day moving average price of $0.70.

Oragenics Company Profile

Oragenics, Inc develops novel antibiotics against infectious diseases and treatments for oral mucositis. It is developing OG716, an antibiotic product candidate, which is in nonclinical testing for healthcare-associated infections, as well as other homolog antibiotic product candidates. The company is also developing AG013, which is in Phase II clinical trial for the treatment of oral mucositis in cancer patients.

Read More: What is the definition of market timing?

Get a free copy of the Zacks research report on Oragenics (OGEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.